What does this research mean for the field?

In patients with relapsed or refractory multiple myeloma undergoing BCMA-directed CAR T-cell therapy, bridging therapy is predominantly administered to those with more advanced and biologically adverse disease, and its efficacy varies significantly depending on the regimen used. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the clinical impact, efficacy, and safety of bridging therapy administered between leukapheresis and cell infusion in patients undergoing BCMA-directed CAR T-cell therapy.

September 5, 2026HaematologicaOpen Access

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

MWMarie Christine Wesener UDUta M. Demel TPThomas Pabst

Discussion

Member takes

Overview

Multicenter cohort study reveals bridging therapy efficacy varies by regimen in relapsed or refractory multiple myeloma, indicating the importance of optimizing pre-infusion disease control.

Key Points

To evaluate the clinical impact, efficacy, and safety of bridging therapy administered between leukapheresis and cell infusion in patients undergoing BCMA-directed CAR T-cell therapy.
Multicenter real-world cohort study of N=399 patients with relapsed or refractory multiple myeloma receiving BCMA-directed CAR T-cell therapy.
Evaluated clinical characteristics and treatment outcomes among 348 patients (87%) who received bridging therapy compared to those who did not.
Patients receiving bridging therapy presented with more advanced, biologically aggressive disease, demonstrating higher rates of high-risk cytogenetics and penta-class refractoriness.
Disease control and response to bridging therapy differed significantly depending on the specific treatment regimen administered prior to CAR T-cell infusion.

Cite This Study

Wesener et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4436b95aff0620ebc8d https://doi.org/10.3324/haematol.2026.301082

View Full Paper

Ask AI

Bookmark

September 5, 2026HaematologicaOpen Access

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

MWMarie Christine Wesener UDUta M. Demel TPThomas Pabst

Discussion

Member takes

Overview

Multicenter cohort study reveals bridging therapy efficacy varies by regimen in relapsed or refractory multiple myeloma, indicating the importance of optimizing pre-infusion disease control.

Key Points

To evaluate the clinical impact, efficacy, and safety of bridging therapy administered between leukapheresis and cell infusion in patients undergoing BCMA-directed CAR T-cell therapy.
Multicenter real-world cohort study of N=399 patients with relapsed or refractory multiple myeloma receiving BCMA-directed CAR T-cell therapy.
Evaluated clinical characteristics and treatment outcomes among 348 patients (87%) who received bridging therapy compared to those who did not.
Patients receiving bridging therapy presented with more advanced, biologically aggressive disease, demonstrating higher rates of high-risk cytogenetics and penta-class refractoriness.
Disease control and response to bridging therapy differed significantly depending on the specific treatment regimen administered prior to CAR T-cell infusion.

Cite This Study

Wesener et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4436b95aff0620ebc8d https://doi.org/10.3324/haematol.2026.301082

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark